Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously untreatable and high-burden diseases. Here, we provide insight into GCT development and regulation activities in Europe, quantify clinical and regulatory success, and compare these with other medicinal products in order to reflect on regulatory changes and challenges
Gene and cell-based therapies (GCTs) are highly innovative therapies and hold great promise in the t...
Advanced therapy medicinal products (ATMPs), i.e., cell and gene therapy products, is a rapidly evol...
Innovative characteristics of gene and cell-based therapy products (GCTs) often hinder standardized ...
Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously unt...
Introduction: New therapies with genes, tissues and cells have taken the emerging field for the trea...
Gene and cell-based therapies (GCTs) have the potential to revolutionize healthcare. Recently, genet...
In the last decade, many clinical trials with gene- and cell-based therapies were performed and incr...
1.BackgroundCommunicating information on the regulatory framework applicable to gene and cell therap...
Gene- and cell-based therapies (GCTs) offer potential new treatment options for unmet medical needs....
Gene- and cell-based therapies (GCTs) offer potential new treatment options for unmet medical needs....
Advanced therapy medicinal products (ATMPs) have a massive potential to address existing unmet medic...
The rapid expansion of the gene therapy pipeline in recent years offers significant potential to tre...
Therapies based on genetically modified cells hold great promise for the treatment of various diseas...
International audienceThe first attempts at hematopoietic stem cell-based gene therapy (HSC-GT) were...
After years of research and development, gene therapies are now becoming a commercial reality with s...
Gene and cell-based therapies (GCTs) are highly innovative therapies and hold great promise in the t...
Advanced therapy medicinal products (ATMPs), i.e., cell and gene therapy products, is a rapidly evol...
Innovative characteristics of gene and cell-based therapy products (GCTs) often hinder standardized ...
Gene and cell-based therapies (GCTs) are said to hold great promise as treatments for previously unt...
Introduction: New therapies with genes, tissues and cells have taken the emerging field for the trea...
Gene and cell-based therapies (GCTs) have the potential to revolutionize healthcare. Recently, genet...
In the last decade, many clinical trials with gene- and cell-based therapies were performed and incr...
1.BackgroundCommunicating information on the regulatory framework applicable to gene and cell therap...
Gene- and cell-based therapies (GCTs) offer potential new treatment options for unmet medical needs....
Gene- and cell-based therapies (GCTs) offer potential new treatment options for unmet medical needs....
Advanced therapy medicinal products (ATMPs) have a massive potential to address existing unmet medic...
The rapid expansion of the gene therapy pipeline in recent years offers significant potential to tre...
Therapies based on genetically modified cells hold great promise for the treatment of various diseas...
International audienceThe first attempts at hematopoietic stem cell-based gene therapy (HSC-GT) were...
After years of research and development, gene therapies are now becoming a commercial reality with s...
Gene and cell-based therapies (GCTs) are highly innovative therapies and hold great promise in the t...
Advanced therapy medicinal products (ATMPs), i.e., cell and gene therapy products, is a rapidly evol...
Innovative characteristics of gene and cell-based therapy products (GCTs) often hinder standardized ...